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The routes of uptake and efflux should be considered when developing new drugs so 32 
that they can effectively address their intracellular targets. As a general rule, drugs 33 
appear to enter cells via protein carriers that normally carry nutrients or metabolites. A 34 
previously developed pipeline that searched for drug transporters using Saccharomyces 35 
cerevisiae mutants carrying single-gene deletions identified import routes for most 36 
compounds tested. However, due to the redundancy of transporter functions, we 37 
propose that this methodology can be improved by utilizing double-mutant strains in 38 
both low- and high-throughput screens. We constructed a library of over 14,000 strains 39 
harboring double-deletions of genes encoding 122 non-essential plasma membrane 40 
transporters, and performed low- and high-throughput screens identifying possible drug 41 
import routes for 23 compounds. In addition, the high-throughput assay enabled the 42 
identification of putative efflux routes for 21 compounds. Focusing on azole antifungals, 43 
we were able to identify the involvement of the myo-inositol transporter, Itr1p, in the 44 
uptake of these molecules and to confirm the role of Pdr5p in their export.  45 
 46 
Importance 47 
Our library of double transporter deletion strains is a powerful tool for rapid 48 
identification of potential drug import and export routes, which can aid in determining 49 
the chemical groups necessary for transport via specific carriers. This information may 50 
be translated into a better design of drugs for optimal absorption by target tissues and 51 
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the development of drugs whose utility is less likely to be compromised by the selection 52 
of resistant mutants. 53 
 54 
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Novel drug candidates are generally designed based on the assumption that they enter 59 
cells by passive diffusion through the plasma membrane lipid bilayer. Thus, compounds 60 
that do not follow the rules predicting an efficient diffusion through the lipid bilayer are 61 
not considered drug-like and are discarded early in the drug discovery process. 62 
However, a growing body of evidence indicates that passive diffusion via the lipid bilayer 63 
is an exceptional, rather than the normal, mode of drug entry (1–6) with most drugs 64 
(and other xenobiotics) entering cells via protein carriers that normally carry nutrients or 65 
metabolites. 66 
 67 
The investigation of the carrier substrate specificity is one of the objectives of the 68 
RESOLUTE consortium, a public-private partnership that aims to study the therapeutic 69 
potential of the human solute carrier (SLCs) proteins superfamily (7). This consortium 70 
works to create tools for studying these proteins on a large scale to associate specific 71 
classes of compounds with particular carriers. Therefore, knockout and tagged 72 
overexpression cell libraries are being built for most SLCs to carry out the 'guilt-by-73 
association' strategy. By using these approaches, the RESOLUTE consortium seeks to 74 
contribute to the inclusion of this superfamily of carriers in the class of classic drug 75 
targets. 76 
 77 
Given the importance of mapping drug-transporter interactions to enabling a rational 78 
targeting of drugs to the tissues of interest, a method was developed to screen for yeast 79 
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transmembrane proteins that mediated drug absorption; this identified the import 80 
routes for half of the screened anticancer compounds (8). The strategy assumes that a 81 
drug is toxic when present inside the cell in high concentration; thus, if the yeast does 82 
not have the carrier protein responsible for the entry of that molecule, it becomes drug 83 
resistant and survives (Figure 1). Strains with deletions of individual genes encoding 84 
each of the non-essential transporters of the Saccharomyces cerevisiae plasma 85 
membrane were employed for transporter identification (8). The same approach was 86 
also used to study the specificity of human solute carriers on the import of 60 cytotoxic 87 
compounds using an SLC-specific CRISPR – Cas9 knockout (KO) library, suggesting the 88 
association between SLCs and the transport of 47 out of 60 compounds (~ 80%) (9), a 89 
proportion similar to that observed in the yeast study (18/26; ~ 70%) (8). In addition, 90 
CRISPR – Cas9 was also employed for large-scale transporter disruption in S. cerevisiae 91 
strains, aiming at the identification of carrier-mediated routes (10). 92 
 93 
Yeast deletion libraries have been widely used, in genomic chemical-profiling strategies, 94 
to study cellular responses to both new molecules and established drugs (11). In this 95 
approach, libraries with heterozygous deletions of all genes (haploinsufficiency profiling 96 
- HIP) or homozygous non-essential genes (homozygous deletion profiling - HOP) are 97 
employed in genetic screens to evaluate the cellular response to these molecules. 98 
Extensive studies have tested large numbers of molecules (12, 13) using these 99 
approaches and the data are available to the research community. Based on the strategy 100 
previously presented for the identification of xenobiotic transporters, HOP data for 101 
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strains with deletions of membrane transporters can provide insights into possible 102 
routes of entry for the screened molecules. However, the experimental design 103 
employed in most HOP assays aims to identify strains sensitive to low concentrations of 104 
test compounds and is not directly comparable to screens utilizing toxic concentrations 105 
(as required for transporter identification assays). Furthermore, proteins and drugs are 106 
highly promiscuous, with many drugs interacting with multiple off-target proteins in 107 
most cells (14). This promiscuity is not exclusive to the intracellular targets of drugs, but 108 
also occurs in the trans-membrane import and export of drug compounds (15). 109 
 110 
Due to the redundancy of transport functions between transmembrane proteins, we 111 
concluded that a larger set of drug import routes could be identified by testing drug 112 
import activity in strains lacking pairs of transporters. Hence, to screen for epistatic 113 
interactions between genes encoding transporter proteins, we constructed a library of S. 114 
cerevisiae strains containing double-deletion mutations of all pairwise combinations of 115 
genes that specify non-essential transmembrane transporters. We have characterized 116 
the performance of this double-mutant collection in drug screening, employing both 117 
low- and high-throughput strategies (Figure 2). These studies have reinforced our initial 118 
hypothesis that most drugs enter cells preferentially through plasma membrane 119 
transporters. 120 




Double-deletion library construction 123 
The library with 14,640 strains carrying double deletions of genes encoding non-124 
essential membrane transporters was built utilizing the Synthetic Genetic Arrays (SGA) 125 
methodology. Genetic crosses were performed between a strain carrying a deletion due 126 
to replacement of a transporter gene with the kanMX cassette flanked by up- and down-127 
stream barcodes for tracking deletions and a second transporter deletant containing the 128 
natMX replacement cassette, but without the barcodes. Non-essential gene deletants 129 
were selected (from the library of strains available in the laboratory) based on their 130 
transporter function and plasma membrane expression (16). 131 
 132 
Commercial xenobiotics cytotoxic to yeast 133 
To allow a further characterization of our transporter double-deletion library, and 134 
determine plasma membrane import routes for different xenobiotic compounds, we 135 
purchased 32 compounds that largely obey the Lipinski’s “rule of 5” (17) and are 136 
therefore expected to be preferentially imported into the cells by passive diffusion 137 
through the lipid bilayer (Table S1). The carrier-mediated import route of 13 of these 138 
compounds had been evaluated previously (8), using a single-transporter gene-deletion 139 
library. However, this earlier study was not able to define the specific transporter for all 140 




We determined an approximate IC90 for each compound’s effect on yeast in liquid 143 
cultures and proceeded to select for resistance in plates with sub-lethal doses of each 144 
compound. We performed serial dilutions of wild type (BY4741), the transporter double-145 
mutant, and single-mutant pools and spotted these onto YNB+Sc agar plates with 146 
inhibitory concentrations of the commercial xenobiotics (Figure 3). Single-gene deletion 147 
mutants for genes encoding cytoplasmic non-transporter proteins were included 148 
(trx2Δ::kanMX and cpr1Δ::kanMX) as controls. The xenobiotics for which we did not 149 
observe significant growth inhibition at 200 μM (maximum of 2% DMSO; 400 μM for 150 
artesunate and 800 μM for dl-4-hydroxy-3-methoxymandelic acid and tamoxifen) in 151 
solid media were excluded from further screens (Figure 3).  152 
 153 
Using spot assays, we defined which compounds were toxic to yeast in solid media and 154 
the appropriate concentration to inhibit the growth of the wild type strain whilst 155 
selecting for resistant strains from the library pool. For some compounds, we were able 156 
to observe a clear difference in resistance between wild type and the transporter 157 
deletants, as shown in Figure 3. In addition, we were able to identify compound-158 
inhibitory differences between double- and single-deletant libraries. It is expected, for a 159 
compound imported by a transporter, that the double-deletion library will present 160 
double the number of resistant strains than the single-deletion library, even when only 161 
one transporter is involved in the uptake. We saw this pattern on using inhibitory 162 
concentrations of 1,2,4-triazoles (epoxiconazole, difenoconazole, and tebuconazole) and 163 
chlorothalonil, for example (Figure 3). Thus, working with a double-deletion library can 164 
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facilitate the identification of transporters. However, in several cases we observed more 165 
colonies in the single-deletion library that could be due to differences in strain 166 
background, as a number of different markers were introduced in the double mutant 167 
strains to allow large-scale selection of the desired haploids. 168 
 169 
We employed two approaches for compound transporter identification: a low- and a 170 
high-throughput strategy. The low-throughout method is a plate-based screen with the 171 
selection of resistant strains in the presence of inhibitory concentrations of xenobiotics 172 
and identification of transporter deletions bearing the kanMX cassette by barcode 173 
sequencing. This strategy allows a visual assessment of a possible involvement of 174 
transporters in drug uptake and the identification of candidate import routes. The 175 
second approach was the high-throughput screening, where we evaluated the 176 
fluctuation of abundance of transporter-deletion strains by sequencing the kanMX 177 
upstream barcodes from the library pool in a liquid culture containing inhibitory 178 
concentrations of a compound. This screening allowed us to identify not only strains 179 
resistant to a given compound, but also strains sensitive to this compound. 180 
 181 
Low-throughput (plate-based) strategy for xenobiotic transporter identification 182 
Xenobiotic-resistant strains from the transporter double-deletion library pool were 183 
selected by plating 106, 105, 104 and 103 colony-forming units (CFUs) of wild type BY4741 184 
or the transporter-deletion pool onto YNB+Sc agar plates containing inhibitory 185 
concentrations of the compounds (Figure 4 and data not shown). We expected to 186 
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observe an even growth inhibition of the wild type strain and the appearance of 187 
resistant colonies (corresponding to the deletion of genes encoding transporters 188 
responsible for drug uptake) on plates where the compounds enter cells through plasma 189 
membrane transporters. For the selection of xenobiotic-resistant strains from the library 190 
pool, we investigated the difference between the number of resistant colonies, aiming 191 
to define conditions in which more deletant colonies could grow on the pool plate in 192 
comparison to that of the wild type. However, we also observed cases in which the 193 
greatest differences between wild type and transporter deletion pools were the 194 
formation of colonies with different sizes, hence we collected the largest colonies to 195 
identify the deleted carrier gene. This was the case for 5-fluorocytosine and fluconazole, 196 
for example (Figure 4). Once 20-40 resistant colonies were selected for each xenobiotic, 197 
barcodes (associated with kanMX cassette) from approximately 20 strains were 198 
sequenced to identify the transporter-genes that had been deleted.  199 
        200 
After aligning the sequenced barcodes to the Saccharomyces Genome Deletion Project’s 201 
barcode list (18), we identified the genes deleted in each compound-resistant strain 202 
(Table 1). It is important to note that, as only the genes deleted with kanMX were 203 
barcoded, the sequencing results only show one of the transporter-encoding genes 204 
deleted in the compound-resistant strain. Furthermore, as during the library 205 
construction we had several copies of the his3 deletion in all mating plates, this deletion 206 
is present in high frequency in the library. Hence, HIS3 “hits” were excluded from further 207 
data analysis. As expected, for 5-fluorocytosine, the positive control of the study, 7 out 208 
12 
 
of 10 of the carriers identified by deletion with the kanMX cassette correspond to Fcy2p 209 
(gene FCY2 - YER056C). For the other three 5-fluorocytosine resistant strains selected, 210 
the deletion of FCY2 was identified by PCR with the natMX cassette (data not shown). 211 
 212 
Analyzing the results in plate assays (Table 1), we could observe recurrent transporter-213 
gene deletions for some compounds. This is best exemplified by the ketoconazole 214 
results, where 14 resistant strains were nha1Δ. Other compounds showed preferential 215 
representation of certain transporter-gene deletion strains, indicating their potential 216 
involvement in compound import. Although these results suggested possible 217 
transporters, additional assays are needed to confirm these phenotypes. In fact, plate-218 
screening assays can give rise to false positives, requiring a larger sample size to confirm 219 
the hits. Thus, for a more comprehensive screening, with the monitoring of the 220 
fluctuation in the abundance of all strains in the pool, we performed a high-throughput 221 
assay in liquid culture.  222 
 223 
High-throughput (liquid-growth) strategy for xenobiotic transporter identification 224 
The putative import and export routes of xenobiotic compounds were investigated by 225 
Chemical Genomic Profiling (CGP) using our double-mutant non-essential transporter-226 
gene deletion library. The library was cultivated in liquid cultures containing inhibitory 227 
concentrations of xenobiotics for ca. 15 generations and the kanMX upstream barcodes 228 
from the population were sequenced for transporter-gene deletion identification. Thus, 229 
we were able to identify deletions responsible for resistance (putative import route) and 230 
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sensitivity (putative export route) to the test compounds (Figure 5, Table 1, Data set S1). 231 
Treatment with 5-fluorocytosine identified the fcy2Δ mutant as the most abundant 232 
strain of the assay, confirming the accuracy of the method.  233 
 234 
Among the significantly less abundant strains (padj ≤ 0.1; p-value ≤ 0.001; log2 fold 235 
change ≤ 0.5), we could identify deletions for genes encoding ATP-binding cassette 236 
(ABC) drug efflux pumps involved in pleiotropic drug resistance: Pdr5p, Snq2p and Yor1p 237 
(19) (Data set S1). The pdr5Δ mutation caused sensitivity to artesunate, irgasan, 238 
iprobenfos, and azoles; the latter being consistent with published results (20, 21). The 239 
snq2Δ mutation caused sensitivity to artesunate, carbendazim, and chlorothalonil. The 240 
yor1Δ mutation caused sensitivity only to tunicamycin. Pdr11p, a PDR family member 241 
involved in sterol uptake (22), was identified among mutations that conferred sensitivity 242 
to artesunate, captan, chlorothalonil, difenoconazole, N-phenylanthranilic acid, 243 
tamoxifen, and tunicamycin. The PDR11 paralog, AUS1, involved in sterol uptake (22), 244 
was not represented among depleted strains. We also identified Nft1p, a putative 245 
transporter of the MRP subfamily (23), as a candidate exporter for epoxiconazole, 246 
tebuconazole, difenoconazole, and 5-fluorocytosine.  247 
 248 
Multi-drug resistance transporters can also belong to the Major Facilitator Superfamily 249 
(MFS) (24, 25); however, these had little impact on sensitivity to our test compounds, 250 
with the following exceptions: flr1Δ (chlorothalonil and 3,4-dicloroisocoumarin), dtr1Δ 251 
(fluconazole), qdr1Δ (5-fluorocytosine), qdr2Δ (5-fluorocytosine), and atr1Δ (5-252 
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fluorocytosine). It should be noted that some transporters of this class (e.g. Flr1p) have 253 
been reported to be determinants of resistance to compounds tested in this study (e.g. 254 
fluconazole) (26), however, our CGP did not confirm these correlations.  255 
 256 
Principal components analysis (PCA) allows an evaluation of the distribution of 257 
variations between replicates and conditions within an experiment. Figure 6 and Figure 258 
S1 show that the strain composition in the pool following some treatments is very 259 
similar to the control (DMSO) in both the first and second principal components. It is 260 
important to note that replicates of each xenobiotic cluster within the same region of 261 
the PCA plot, and that the azoles tested (with the exception of fluconazole) present very 262 
similar strain composition profiles, which validates the reproducibility of the 263 
experiments. We would also note that 5-fluorocytosine (Figure S1) shows a very 264 
different profile when compared to all other treatments in the analysis, with the 265 
exception of fluconazole (Figure 6). 266 
 267 
Overview of putative import routes for the xenobiotics 268 
Some of the compounds evaluated in our assays were not cytotoxic in either liquid or 269 
solid medium at the highest concentrations tested (typically 200 µM of compound 270 
corresponding to 2% DMSO in the medium) which prevented us from performing the 271 
downstream experiments to identify resistant strains and suggest import routes.  To 272 
propose possible transport routes for all the other compounds tested, we evaluated the 273 
results obtained from both low- and high-throughput assays (Table 1). In addition, we 274 
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performed high-density plate-based assays with 308 strains selected from the double-275 
deletion library to evaluate the profile of resistance in the presence of the xenobiotics 276 
tested. We highlight below some interesting results and propose transporter 277 
relationships for some compounds. 278 
 279 
Tunicamycin is a nucleoside antibiotic that inhibits N-glycosylation of asparagine in 280 
eukaryotes and the use of this substance is important for the study of the UPR (unfolded 281 
protein response) signaling network (27). In the plate assay, we identified Fur4p as a 282 
possible tunicamycin carrier, since its deletion was present in 11 of the 20 resistant 283 
colonies analyzed (Table 1). Considering the CGP assay, however, the deletion strain 284 
fur4Δ did not appear significantly abundant (Table 1). However, in the high-density 285 
assay, the double mutant pdr5::natMX fur4::kanMX showed a resistant phenotype (F18; 286 
Figure S2).  The reciprocal double mutant, fur4::natMX pdr5::kanMX did not grow in 287 
either the treatment or control plates (I03; Figure S2). It is possible to identify a plate 288 
effect in this row, in which more double mutants show resistance, and this result should 289 
be carefully evaluated. Fur4p acts as a uracil permease (28, 29), which indicates that its 290 
contribution to the entry of the compound tunicamycin may be due to interaction with 291 
the uracil moiety present in the structure of this compound. In a previous study (8), the 292 
transporters Lem3p, Dnf2p, and Qdr2p were identified as responsible for the entry of 293 
tunicamycin into the cell. The absence of Lem3 and Dnf2 transporters in the double-294 
mutant library tested in our work and of fur4Δ among the deletions tested previously (8) 295 
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prevents the cross-validation of the two results. Thus, the previous and current results 296 
indicate the involvement of Dnf2p, Lem3p and Fur4p in the uptake of tunicamycin.  297 
 298 
Tamoxifen is an anti-tumorigenic selective estrogen receptor modulator (30, 31). The 299 
plate assay and the high-density assay revealed that deletions of the TPO5 and NHA1 300 
genes resulted in resistance to the compound in solid medium (Table 1; Figure S3). 301 
Nha1p acts as a cation antiporter (32–34) and Tpo5p is a putrescine and spermidine 302 
exporter; however, it localizes to the Golgi and post-Golgi vesicles (35). In the high-303 
density assay, however, only the double mutant tpo5::natMX nha1::kanMX showed a 304 
resistance phenotype, and the strain nha1::natMX tpo5::kanMX was not resistant 305 
(Figure S3). It is important to note that the deletion nha1::kanMX appears in other 306 
resistant strains obtained in the high-density assay, which may indicate that the 307 
resistance is due to a strain background effect and not a specific consequence of the 308 
transporter deletion. To investigate this possibility, we performed spot tests with 309 
nha1::kanMX and nha1::natMX mutants in combination with 12 different transporters 310 
and his3 as negative control (data not shown). In all cases, we observed that 311 
nha1::kanMX conferred resistance to tamoxifen whereas the same was not always 312 
evident for nha1::natMX. nha1::natMX was resistant to tamoxifen in combination with 313 
approximately 50% of the transporter deletions tested: itr1::kanMX, tpo5::kanMX, 314 
mal11::kanMX, zrc1::kanMX, dnf1::kanMX, or fcy2::kanMX (none of which was 315 
previously identified as resistant to the drug). This suggests that there could have been a 316 
mutation in the original nha1::natMX that leads to an increased sensitivity to tamoxifen 317 
17 
 
and is present in half of the spores produced in the library. The same pattern was not 318 
evident for azoles. Considering the CGP assay, the most abundant strains (log2 fold 319 
change ≥ 0.5) in the tamoxifen-treated pool were the adp1Δ and tna1Δ mutants (Table 320 
1). Adp1 is a putative ATP-dependent permease (36) and Tna1p is a high-affinity 321 
nicotinic acid permease (37). Although the tpo5Δ and nha1Δ mutants had a log2 fold 322 
change above zero, it was not greater than 0.5. Thus, there is a clear difference in 323 
resistance between cells grown on solid and in liquid media. 324 
 325 
Carbendazim is a benzimidazolic carbamate fungicide that acts by inhibiting the 326 
polymerization of microtubules by interaction with β-tubulin (38). Some carrier 327 
deletions were found as resistant strains in the plate assay and among the abundant 328 
strains of the CGP (Table 1). Considering those with a log2 fold change ≥ 0.5, we have: 329 
tna1Δ, nft1Δ, nha1Δ, and pdr5Δ; with a log2 fold change between 0 < 0.5: yor1Δ, ady2Δ, 330 
and ybt1Δ. Tna1p is a high-affinity transporter of nicotinic acid, a pyridinecarboxylic acid 331 
(37), and may be directly involved in the entry of carbendazim. It is worth noting the 332 
presence of the carboxylic acid group among the natural substrates for transporters 333 
identified as hits for carbendazim, as nicotinic acid for Tna1p and acetate for Ady2p.  On 334 
the other hand, Nha1p may only make an indirect contribution to the drug’s ingress due 335 
to its function as a cation antiporter. It is noteworthy that, we identified the ABC family 336 
members Yor1p, Ybt1p and Nft1p (multidrug resistance protein - MRP-subfamily) (23, 337 
39), as putative importers. We also identified Pdr5p as a putative importer of 338 
carbendazim, which is interesting since this protein is typically described as an exporter. 339 
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Validation plate assays using the single-mutant pdr5Δ growing in an inhibitory 340 
concentration of carbendazim (data not shown) indicated that this deletion provides 341 
resistance to this compound, corroborating the involvement of Pdr5p in carbendazim 342 
uptake.  343 
 344 
We performed validation experiments to investigate the resistance of double mutants 345 
enriched in CGP to 1,10-phenanthroline (Figure 7). Amongst the strains enriched in the 346 
CGP were fui1Δ, arn1Δ, arn2Δ, and enb1Δ. Fui1p is a high affinity uridine permease and 347 
the transporters Arn1p, Arn2p and Enb1p have similar cargo specificity (ARN 348 
family transports siderophore-iron chelates and Enb1p transports ferric enterobactin) 349 
whereas Ftr1p is a high-affinity iron permease, which is also involved in iron 350 
homeostasis. However, ftr1Δ strains were depleted in CGP assays. Even though Arn1p, 351 
Arn2p, Enb1p, and Ftr1p are iron transporters, only the transporters with specificity for 352 
large molecules, such as Arn1p, Arn2p, Enb1p, and Fui1p appear to contribute to 1,10-353 
phenanthroline transport. Single transporter deletions or deletions in combination with 354 
ftr1Δ do not confer resistance probably due to redundancy. Only with the deletion of at 355 
least 2 of the 4 suggested transporters can we limit the compound’s uptake to confer 356 
measurable resistance. Our results demonstrate the power of the double-mutant 357 
deletion library in identifying groups of transporters that contribute to the import of the 358 




Validation of transporter-mediated import routes of Azoles 361 
With the exception of fluconazole, azole compounds showed very consistent results 362 
with regards to their import and export routes (evident in the PCA plot, Figure 6). Azoles 363 
are antifungal agents that target the ergosterol (sterol) biosynthesis pathway by 364 
inhibiting lanosterol 14-alpha demethylase (a cytochrome p450), encoded by the ERG11 365 
gene in S. cerevisiae (21, 40, 41). When analyzing the correlation between the CGP 366 
results of six azole compounds, we found that three azole antifungals (difenoconazole, 367 
epoxiconazole, and tebuconazole) show very similar profiles of genes involved in the 368 
import and export of these compounds (r2> 0.95) (Figure 8B, C, and F). These antifungal 369 
agrochemicals are members of the 1,2,4 - triazole class and also present a halogenated 370 
benzene ring (2 in difenoconazole and epoxiconazole; 1 in tebuconazole) (Figure 8G). 371 
The azole antifungals of the imidazole class, clotrimazole and ketoconazole, are drugs 372 
for animal use and they also have a good correlation between importers and exporters 373 
(r2 = 0.97) (Figure 8A and E). Fluconazole did not show any correlation with the other 374 
azoles (Figure 8D). This may be due to differences in its structure, as this compound 375 
bears an additional nitrogen-containing five-membered ring and a difluorophenyl group. 376 
These results indicate that there is a clear relationship between compound structures 377 
and the import/export routes revealed by our chemogenomic approaches. Previous 378 
studies suggested that the azoles use facilitated diffusion and that both parts of the 379 
molecule (the nitrogen-containing five-membered and the halogenated benzene rings) 380 
are essential for cell uptake (42–44). We have demonstrated that these chemical groups 381 
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show strong correlation to the substrate profile of protein transporters involved in the 382 
influx and efflux of the xenobiotics. 383 
 384 
CGP and low-throughput assays of azole compounds showed an interesting profile of 385 
putative import and export routes (Figure 8 and Table 1), suggesting a number of 386 
carriers potentially responsible for azole uptake. The nha1::kanMX deletion mutant, for 387 
example, was a top hit for 5 of the 6 azoles tested (CGP) and nha1Δ deletants were 388 
identified among the resistant colonies selected in a plate assay (low-throughput assay) 389 
for clotrimazole, ketoconazole, and difenoconazole (Table 1), supporting the possible 390 
involvement of this cation antiporter in the transport of these compounds. Itr1p, which 391 
is responsible for uptake of myo-inositol (45), is a putative import route, as itr1Δ strains 392 
are resistant to the triazoles difenoconazole, epoxiconazole, and tebuconazole in both 393 
assays (Table 1). In accordance with this finding, we observed that most of the double-394 
deletion strains resistant to triazoles in the high-density plate assay bear the deletion of 395 
the ITR1 gene (Figure S4, Figure S5, and Figure S6). We also observed the resistance of 396 
itr1Δ to the imidazoles clotrimazole and ketoconazole in the high-density assay (Figure 397 
S7 and Figure S8). This is in agreement with previous work (8) in which the deletion of 398 
ITR1 conferred resistance to the compounds clotrimazole, ketoconazole, and 399 
fluconazole in plate experiments.   400 
 401 
Evaluating the results obtained with the compound fluconazole, an azole of the triazole 402 
class, we observe a group of transporters, the deletion of which conferred a resistance 403 
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phenotype in both plate and CGP approaches. The small- and large-scale screening 404 
showed that the following deletions may confer resistance to this compound and thus 405 
implicate the cognate transporters in the import of fluconazole: qdr3Δ, tat1Δ, ady2Δ, 406 
adp1Δ, yor1Δ, arn1Δ, hxt4Δ, bor1Δ, and hol1Δ. We did not perform further validation 407 
experiments for these transporters; however, the set of deletions that conferred 408 
resistance to fluconazole are different from those observed for other azoles and may 409 
contribute to the traffic of this compound. 410 
 411 
Itr1p is a putative azole importer 412 
We investigated the role of Itr1p on azole import by evaluating the resistance 413 
phenotype of itr1Δ, either alone or combined with itr2Δ, nha1Δ, pdr5Δ mutations. Small-414 
scale assays confirmed the resistance phenotype (in plate-assays and CGP) of itr1Δ 415 
strains to difenoconazole, epoxiconazole, ketoconazole, and tebuconazole in both solid 416 
and liquid media assays (Figure 9 and data not shown). However, in the spot test, the 417 
itr1Δ mutant did not present a strong resistance phenotype in the presence of either 418 
clotrimazole or fluconazole.  419 
 420 
Considering the important role of Pdr5p in azole efflux (20, 21), we investigated whether 421 
the resistance phenotype observed for the strain was due to the absence of the 422 
importer or to an activity of the exporter. We performed spot tests of BY4741 (wild 423 
type) and mutant strains in the presence of sub-lethal doses of the agrochemical 424 
triazoles, ketoconazole, clotrimazole, and fluconazole (Figure 9A). Our results show that 425 
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a cell containing all transporters (importers and exporters) is sensitive to these 426 
compounds and that export pumps cannot overcome their import. The double mutant 427 
pdr5Δ his3Δ was sensitive to azoles, corroborating previous findings that suggest a role 428 
for this multidrug transporter in the export of azole compounds (20, 21) (Figure 9A). We 429 
found that the double mutant strain itr1Δ pdr5Δ is sensitive to azoles, which indicates 430 
that azoles accumulate inside the cell even in the absence of Itr1p, suggesting additional 431 
import routes for azole compounds (Figure 9A). Hence, without an efficient efflux 432 
through Pdr5p, the cell is susceptible to the action of azoles even when its primary 433 
import route is absent.  434 
 435 
Our approaches suggest a group of transporters that may contribute with Itr1p in azole 436 
uptake. In CGP and the high-density plate-assay results, we observed that treatment 437 
with the agrochemical triazoles and ketoconazole selected a set of deletions that, in 438 
combination with itr1Δ, confer resistance phenotypes to the double mutants (Figure S4, 439 
Figure S5, Figure S6, and Figure S8), namely tpo5Δ, ftr1Δ, snq2Δ, smf1Δ, tpo1Δ, tna1Δ, 440 
and adp1Δ. We also investigated itr2Δ, as ITR2 is a paralog of ITR1, encoding a putative 441 
azole importer. However, in our plate assay (Figure 9B), the itr2Δ mutant did not confer 442 
resistance to azoles. Nha1p was also suggested as a putative azole importer, considering 443 
that nha1::kanMX was the top CGP hit for azoles and also presented as a hit in the low-444 
throughput assay (Table 1). However, validation studies with nha1::natMX showed no 445 
resistance profile (Figure 9C), which may suggest that some nha1::kanMX strains might 446 
23 
 
carry additional mutations, for instance in genes specifying cytochrome P450s (46), that 447 
could be responsible for the observed phenotype.  448 
 449 
Discussion 450 
There is considerable controversy regarding the preferential mode of import of drugs 451 
into their target cells. The norm in the pharmaceutical industry is to design new drugs 452 
on the principle that they should be able to enter cells by passive diffusion through the 453 
plasma membrane lipid bilayer. However, this does not explain the fact that there are 454 
many efficacious drugs on the market whose physicochemical characteristics make it 455 
unlikely that they enter by this route (47). Furthermore, import by non-specific passive 456 
diffusion does not explain the differences in drug import between different tissues and, 457 
in particular, the inability of many drugs to enter the brain (2). An alternative is that, for 458 
many drugs and other xenobiotics, the primary route of ingress is likely via protein 459 
carriers located in the plasma membrane that can affect either facilitated diffusion or 460 
active transport (2, 48). In order to evaluate the primary route of import of xenobiotics 461 
and identify any transporter(s) responsible for their entry into target cells, we 462 
assembled a collection of yeast strains that lacked the genes encoding either a single or 463 
a pair of membrane transporters that can be used to rapidly evaluate whether specific 464 
transporters were involved in the import or export of individual drugs by observing the 465 




The library used in this work contains double-deletions of non-essential transporters, 468 
and provides at least a two-fold increase in resistant strains compared to the single-469 
deletion library, thus enabling the identification of pairs of transporters involved in the 470 
entry of toxic compounds. Two strategies were employed for transporter identification: 471 
low-throughput (plate assay) and high-throughput assays (CGP), using a pool of the 472 
double-mutant library, combined with validation assays with isolated strains. The low-473 
throughput approach clearly yields valuable and verifiable results; however, it is 474 
laborious and demands high sampling to obtain significant data. Alternatively, we 475 
employed high-throughput assays, where pools of double-mutant transporter-deletion 476 
strains were grown in competition and the relative contribution of each transporter to 477 
the import or export of a given test compound was inferred from the resistance 478 
(enrichment) or sensitivity (depletion) phenotypes conferred by their deletion. CGP 479 
provided quantitative clues to the relative contribution of each transmembrane protein 480 
to the transport of different compounds across the plasma membrane. 481 
 482 
Out of 21 compounds tested in CGP in this work, 14 selected for significantly enriched 483 
strains, among which we were able to observe the same deletion strains as hits from the 484 
low- and high-throughput screens. For example, CGP, low-throughput, and high-density 485 
assays suggested putative yeast plasma membrane transporters for cytotoxic 486 
compounds and indicated that the myo-inositol transporter Itr1p plays a significant role 487 
in the uptake of azoles (both triazoles and imidazoles), which is in agreement with 488 
previous work that indicated the entry of azoles into the cell is via facilitated diffusion in 489 
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an ATP-independent process (42–44). CGP also provided consistent resistance and 490 
sensitivity data for the triazole agrochemicals and the clinically important imidazoles, 491 
identifying not just influx carriers, but also the efflux pumps that may export these 492 
xenobiotics. We were able to identify the ABC multidrug resistance transporter Pdr5p 493 
(19) as the exporter of the 6 azole compounds tested, a result consistent with previous 494 
studies (20, 21). Given the importance of efflux carriers in drug resistance (49), 495 
characterizing the specificity of these carriers could contribute to the development of 496 
drugs refractive to transport via ABC transporters, or the development of therapies in 497 
which the primary drug is used in combination with an export pump inhibitor. 498 
 499 
Competition assays between azoles and myo-inositol did not confer azole resistance 500 
(data not shown) and the double mutant pdr5Δ itr1Δ was also sensitive to azole 501 
treatment, indicating that an alternative import route is used in the absence of Itr1p. 502 
Furthermore, in spite of the evidence suggesting the import of azoles by Itr1p, the 503 
deletion of ITR2, a paralog of ITR1 generated by the whole-genome duplication event, 504 
did not provide a resistance profile for the strain. Both transporters are responsible for 505 
uptake of myo-inositol and have high sequence homology (45), however, our screen 506 
indicates that Itr2p is unlikely to be involved in azole import. Itr1p is described as the 507 
major transporter of myo-inositol and Itr2p plays only a minor role (45), which may 508 
explain the differences in the resistance profiles observed between itr1Δ and itr2Δ 509 




In a search for transporters that may be either secondary azole transporters or have an 512 
indirect effect on these drugs’ efficacy, we focused on nha1Δ, which was a recurrent hit. 513 
Nha1p is a Na+/K+ antiporter that acts in the active export of alkaline cations (Li+, Na+, K+ 514 
and Rb+) (32–34). It was not immediately obvious how Nha1p could be directly 515 
responsible for azole import. Hence, we performed validation experiments using the 516 
double mutants nha1::natMX his3::kanMX, itr1::natMX nha1::kanMX, and  nha1::natMX 517 
itr1::kanMX (Figure 9C). Whilst the nha1::kanMX deletant was resistant to azoles in both 518 
low- and high-throughput assays (we were only able to track the kanMX barcodes), we 519 
did not observe any resistance profile for nha1::natMX his3::kanMX, a strain bearing the 520 
Itr1 transporter. Hence the presence of nha1Δ as a top hit may be due to additional 521 
mutations in the strain carrying nha1::kanMX.  522 
 523 
Our library consists of approximately 14,000 strains constructed by crossing 122 524 
transporter-gene deletions (kanMX marker with barcodes) with 120 transporter-gene 525 
deletions (natMX marker without barcodes). Considering all the combinations, we have 526 
double deletions of importers and exporters that can improve the identification of 527 
transport routes. We believe that this strategy for identifying which transporters are 528 
involved in the transport of specific compound could be improved by performing 529 
pairwise crosses of all non-essential transporter-gene deletions (including genes not 530 
represented in our library) barcoded in both alleles to better represent all non-essential 531 
import routes and facilitate the identification of transporter pairs working in xenobiotic 532 
import. With the development of new strategies for mapping compound import and 533 
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export routes, we aim to contribute to our understanding of resistance mechanisms, 534 
which is critical for the design of drugs with continued efficacy. Furthermore, the 535 
knowledge of transporter substrate specificity may allow the design of pro-drugs with 536 
enhanced targeting to the cell type of interest. Hence, we are convinced that our 537 
double-deletion library is an invaluable tool for the design of more specific and efficient 538 
therapies. 539 
 540 
Materials and Methods 541 
 542 
Media 543 
The following media were used for the construction of the double-mutant collection by 544 
SGA (50–52): YPD (2% bacto peptone, 1% yeast extract, 2% glucose, 2% agar) with G418 545 
(200 mg/L) or clonNAT (100 mg/L); enriched sporulation medium (20 g/L agar, 10 g/L 546 
potassium acetate, 1 g/L yeast extract, 0.5 g/L glucose, 12.5 mg/L histidine, 12.5 mg/L 547 
lysine, 12.5 mg/L uracil, 62.5 mg/L leucine); selective YNB medium (6.7 g/L yeast 548 
nitrogen base with ammonium sulfate and w/o amino acids, 50 mg/L canavanine, 50 549 
mg/L thialysine, 150 mg/L leucine, 40 mg/L uracil, 40 mg/L methionine, 2% glucose); and 550 
YNB/MSG medium (1.7 g/L yeast nitrogen base w/o ammonium sulfate and w/o amino 551 
acids, 1 g/L monosodium glutamic acid, 100 mg/L clonNAT, 200 mg/L G418, 50 mg/L 552 
canavanine, 50 mg/L thialysine, 150 mg/L leucine, 40 mg/L uracil, 40 mg/L methionine, 553 




Drug sensitivity assays for determination of the inhibitory concentrations of xenobiotics 556 
and for selection of resistant strains were performed in YNB+Sc medium (6.7 g/L yeast 557 
nitrogen base with ammonium sulfate and without amino acids, complete amino acid 558 
supplement, 2% glucose), with or without 2% bacto agar.  559 
 560 
Commercial xenobiotics 561 
We selected commercial xenobiotics, including agrochemicals and drugs for both human 562 
and animal use, and prepared 10 mM stock solutions (20 mM for artesunate; 40 mM for 563 
dl-4-hydroxy-3-methoxymandelic acid and tamoxifen) in 100% DMSO of the compounds 564 
purchased from Sigma-Aldrich (Merck Group) (Table S1). We selected 5-fluorocytosine 565 
(Catalog number F7129 - Sigma Aldrich, Merck Group) as a positive control for the 566 
assays as the deletion of FCY2 (YER056C; encoding the purine-cytosine permease) is well 567 
characterized and provides a resistant phenotype to this compound (8, 53). 568 
 569 
Strains 570 
A double-mutant S. cerevisiae library was constructed by crossing single mutant strains 571 
in the BY741 (MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0) background (54) with single 572 
mutant strains in the Y7092 (MATα; can1Δ::STE2pr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 573 
ura3Δ0; met15Δ0) background (51, 52). In BY4741 genetic background, one of the 574 
following plasma membrane transporter encoding genes was replaced with the 575 
antibiotic resistance marker kanMX, flanked by unique sequences (genetic barcodes) 576 
identifying deletions in each of the following open reading-frames: YAL067C, YBL042C, 577 
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YBR008C, YBR021W, YBR043C, YBR068C, YBR069C, YBR180W, YBR294W, YBR295W, 578 
YBR296C, YBR298C, YCL025C, YCR010C, YCR011C, YCR028C, YCR098C, YDL199C, 579 
YDR011W, YDR046C, YDR345C, YDR384C, YDR387C, YDR406W, YDR497C, YDR508C, 580 
YDR536W, YEL063C, YEL065W, YER056C, YER145C, YER166W, YFL011W, YFL040W, 581 
YFL050C, YFL055W, YGL077C, YGL114W, YGL255W, YGR055W, YGR121C, YGR138C, 582 
YGR217W, YGR224W, YGR260W, YGR281W, YGR289C, YHL016C, YHL040C, YHL047C, 583 
YHR092C, YHR094C, YHR096C, YIL013C, YIL088C, YIL120W, YIL121W, YJL093C, YJL129C, 584 
YJL212C, YJL214W, YJR040W, YJR054W, YJR152W, YKL174C, YKL217W, YKR039W, 585 
YKR050W, YKR103W, YKR106W, YLL028W, YLL043W, YLL048C, YLL052C, YLL061W, 586 
YLR081W, YLR092W, YLR130C, YLR138W, YLR237W, YML047C, YML116W, YML123C, 587 
YMR011W, YMR177W, YMR243C, YMR279C, YMR319C, YNL065W, YNL142W, YNL268W, 588 
YNL270C, YNL275W, YNL291C, YNL318C, YNR002C, YNR055C, YNR056C, YNR072W, 589 
YOL020W, YOL103W, YOL122C, YOL158C, YOR011W, YOR071C, YOR153W, YOR192C, 590 
YOR202W, YOR273C, YOR306C, YOR328W, YOR348C, YPL036W, YPL058C, YPL092W, 591 
YPL265W, YPL274W, YPR124W, YPR138C, YPR156C, YPR192W, YPR198W, YPR201W 592 
(55). In the Y7092 background, the same plasma membrane transporter-encoding genes 593 
(except YEL063C, YHR096C and YOR202W) were replaced with the natMX marker (50). 594 
In the library construction, strains containing deletions of genes non-related to transport 595 




Construction of the transporter double-mutant library by Synthetic Genetic Array 598 
The construction of the transporter double-mutant collection library was 599 
performed essentially as described by Tong and coworkers (50–52). Briefly, 122 600 
transporter-encoding genes deletion strains (plus the control strain with YOR202W 601 
deletion), in the BY741 background (54) were grown in 384-colony arrays (pinned using 602 
the Singer Rotor HAD, Singer Instruments, UK) on YPD with G418 (200 mg/L) for 1 day at 603 
30oC. In parallel, 120 strains in the Y7092 background (51, 52) were grown in 384-colony 604 
arrays on YPD with clonNAT (100 mg/L) for 1 day at 30oC. Strains of opposite mating 605 
type were then pinned onto fresh YPD plates and allowed to mate at room temperature 606 
for 24 hours. They were then pinned onto YPD+G418+clonNAT and incubated at 30oC for 607 
2 days to select for diploid cells. The diploids were then pinned onto enriched 608 
sporulation medium and incubated at room temperature for 5-10 days. The MATa 609 
meiotic progeny were selected by pinning the sporulated strains onto selective SD 610 
medium and incubated at 30oC for 2 days. Transporter double-mutant MATa strains 611 
were then selected by pinning onto SD/MSG medium and incubating at 30oC for 2 days. 612 
This last step was repeated to ensure that all strains were indeed double mutants. 613 
Double mutants were replicated into 384-well plates with YPD + 15% v/v glycerol and 614 
stored at - 80oC.  Double mutants were also pooled in the ratio of 1:1:1:1:…:1 and stored 615 
in YPD + 15% v/v glycerol in 5 mL aliquots for competition experiments (library pools). 616 
The transporter-deletion library constructed during the current study will be deposited 617 




Determination of inhibitory concentrations of commercial xenobiotics 620 
S. cerevisiae BY4741 was inoculated into 5 mL of fresh YNB+Sc and grown overnight at 621 
30oC with agitation. Then the culture was diluted to OD595 0.1 in 70 μL of YNB+Sc 622 
containing different dilutions of each xenobiotic. The xenobiotics were tested in the 623 
following concentrations: 200 µM, 100 µM, 40 µM, 20 µM, 8 µM, 4 µM, 1.6 µM, 0.8 µM, 624 
0.32 µM and 0.16 µM. Controls containing 2% and 1% DMSO (v/v) were also tested. 625 
Cultures were prepared in quadruplicate in 384-well flat bottom plates and incubated at 626 
30oC, with linear shaking (700 rpm) in the CLARIOstar® (BMG Labtech) plate reader, for 627 
30 hours with OD595 measurements every 10 minutes. Curves derived from the growth 628 
data were smoothed based on the moving average of the 15 closest measurements, and 629 
the growth score was calculated by multiplying the yield (ODmax – ODmin) by the 630 
maximum slope of the curve and dividing by the time taken to reach the maximum 631 
slope, using the data analysis software MARS (BMG Labtech). Non-linear regression for 632 
IC90 definition was performed using GraphPad Prism version 8.0.0 for Windows, 633 
GraphPad Software, San Diego, California USA.  634 
 635 
Spot assays were performed in Petri dishes (90 x 15 mm) containing YNB+Sc with 636 
inhibitory concentrations of a xenobiotic, as defined by growth assays in liquid cultures, 637 
with equivalent volumes of DMSO in negative control plates. Serial dilutions (1:5 638 
dilution) of BY4741, single- and double-mutant library pool and selected single-mutant 639 
strains were spotted onto control or xenobiotic containing plates for selective inhibition 640 
verification and, for definition of inhibitory concentrations, onto solid media using 48-641 
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pin replicators (Sigma-Aldrich, Merck Group). Plates were incubated at 30°C for 2-4 days, 642 
and images were registered with ChemiDoc™ MP (Bio-Rad). 643 
 644 
Selection of resistant strains 645 
Assays were performed on Petri plates (90 x 15 mm) containing YNB+Sc agar with 646 
inhibitory concentration of xenobiotics. Onto these plates, approximately 103, 104, 105, 647 
and 106 CFU of BY4741 or the double-mutant library pool were plated. Plates containing 648 
YNB+Sc with DMSO were used as plating controls. After 2 days of incubation at 30ºC, 649 
growth was registered with ChemiDoc™ MP (Bio-Rad) and resistant colonies from library 650 
pool plates were picked and transferred to fresh non-selective plates. 651 
 652 
Identification of resistant strains 653 
Genomic DNA was prepared as described in Lõoke et al., 2011 (56). Cells from resistant 654 
colonies were lysed by resuspension into 100 μL of 200 mM LiAc with 1% SDS, followed 655 
by incubation at 70°C for 15 minutes. DNA was precipitated by the addition of 300 μL 656 
100% ethanol, followed by briefly vortexing and centrifugation for 3 minutes at 15,000 657 
g. Pellets were washed with 200 μL 70% v/v ethanol, centrifuged for 3 minutes at 15,000 658 
g and air-dried. gDNA pellets were dissolved in 100 μL of ultrapure water, followed by 659 
centrifugation for 15 seconds at 15,000 g. PCR reactions using Taq DNA Polymerase 660 
P1011 (Sinapse Inc) were prepared following the manufacturer’s instructions. Barcode 661 
amplification was performed using primers pairs U1 forward 5’-662 
GATGTCCACGAGGTCTCT-3’ with kanMX reverse 5’-CATCATTGGCAACGCTAC-3’ 663 
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(upstream barcode) or kanMX forward 5’-CTCCTTCATTACAGAAACGG-3’ with D1 reverse 664 
5’-CGGTGTCGGTCTCGTAG-3’ (downstream barcode). PCR products were purified using 665 
the E.Z.N.A.® Gel Extraction Kit (OMEGA Bio-tek) and sequenced by Sanger Sequencing. 666 
For upstream barcode sequencing, primer pTEF seq reverse 5’- CGACAGTCACATCATGCC-667 
3’ was used and for downstream barcode sequencing, primer kanMX forward was used. 668 
Sequencing was performed at Myleus Biotechnology using capillary electrophoresis 669 
(ABI3730) using POP7 polymer and BigDye v3.1. Sequence analyses and barcode 670 
identification was performed based on Saccharomyces Genome Deletion Project 671 
barcode list (18). 672 
 673 
Chemical genomic profiling 674 
Determination of the inhibitory concentration of xenobiotics for transporter deletion 675 
strains was accomplished by growth curve assays of library pools. These were performed 676 
in liquid media in 48-well flat bottom plates with incubation at 30oC, with 500 rpm 677 
double orbital shaking in the CLARIOstar® (BMG Labtech) plate reader, for 48 hours with 678 
OD595 measurements every 10 minutes. Concentrations selected for chemical genomic 679 
profiling were those that inhibited growth of transporter-deletion pools by 680 
approximately 80% whilst allowing the culture to reach the stationary phase in 24 hours.  681 
 682 
The transporter double-deletion library pool was grown in YNB+Sc for 12 hours at 30°C 683 
with agitation. Pools were then diluted to OD600 0.1 in 500 µL of YNB+Sc containing the 684 
xenobiotic compounds in 48-well flat bottom plates (samples were prepared in 685 
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quadruplicate). After 24 hours growth at 30°C with agitation (ca. 5 generations), OD595 686 
was measured, and cultures were diluted 20x in 500 µL of fresh media containing the 687 
xenobiotic and allowed to grow for 12 hours (ca. 10 generations) under the same 688 
conditions. The dilution procedure was repeated, and cultures were allowed to grow 689 
until stationary phase (ca. 15 generations). Cell pellets were collected, and genomic DNA 690 
was extracted using the Wizard® Genomic DNA Purification Kit. Upstream barcodes 691 
were PCR amplified with U1 and U2 primers containing Illumina pre-adaptors for 692 
multiplex barcode sequencing with Illumina HiSeq2500 platform by the University of São 693 
Paulo Functional Genomics Center. 694 
 695 
The quality of the generated reads was analyzed with the FastQC (version 0.11.7) (57) 696 
and MultiQC (version 1.6) (58) software before and after removal of primers and 697 
adapters performed with the Cutadapt tool (version 1.26) (59). DADA2 (version 1.9.1) 698 
(60) was employed to infer amplicon sequencing variants (ASVs) by trimming and 699 
discarding low-quality reads, correcting sequencing errors (denoising) and merging read 700 
pairs. Since it is known that several barcodes have sequences different from those that 701 
were originally described (61), ASVs that did not match any previously described 702 
barcode were assigned to the most similar barcode sequencing if the Levenshtein 703 
distance was equal to or less than 2. If two or more ASVs matched the same barcode, 704 
the read counts of those ASVs were combined. With the DESeq2 package (version 705 
1.20.0) (62), the normalization of counts and the assessment of the differential 706 
abundance of barcodes between samples treated against untreated controls were 707 
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performed. For principal components analysis (PCA), the barcode count matrix was 708 
transformed using the rlog function to standardize the abundance variance between the 709 
different barcodes. Differentially abundant strains were identified using a maximum 710 
likelihood ratio test and normalization between samples was done by the library size 711 
factor method (63). Differentially abundant barcodes in treated versus control 712 
comparisons were considered significant for the p-value adjusted for multiple tests 713 
(padj) by the Benjamini-Hochberg method (≤ 0.1) and p-value less than 0.001. For the 714 
analysis, we used thresholds of log2 fold change at ≥ 0.5 (for resistant strains) and ≤ -0.5 715 
(for sensitive strains). Correlation from 116 genes presented in all azoles data from CGP 716 
was performed using GraphPad Prism version 8.0.0 for Windows, GraphPad Software, 717 
San Diego, California USA. CGP datasets with differential abundance of barcodes are 718 
presented in Data set S1. 719 
 720 
High-density plate assays for transporter validation 721 
Based on chemical-genomic results, 308 double-transporter-deletion mutants were 722 
selected for validation (padj ≤ 0,1; p-value ≤ 0,001; log2 fold change ≥ 0,5). These were 723 
inoculated in 50 μL of YNB + Sc liquid medium in a 384-well plate and grown at 30°C 724 
until saturation (~ 36 hours). Using the Rotor HDA (Singer Instruments, UK), cultures 725 
were stamped in quadruplicate (1536 spots) on plates containing solid YNB+Sc medium 726 
at inhibitory concentrations (1x and 2x) of the test compounds. Cultures were incubated 727 
for 2 days at 30°C and on subsequent days at room temperature (~25°C). Plate photos 728 




Quantification of the growth of strains was performed by analyzing the images in .jpg 731 
format using a python script. The OpenCV package contour detection module for python 732 
was used to delimit the plate and some colonies in the image. Based on this, the 733 
identification of the 1536 spots and delimitation of the columns and lines of the plate 734 
was performed. Voids (16 spots without culture inoculation; 4 corners of the plate) and 735 
wild type 288 spots (BY4741; plate edge) were identified. For each spot, a quadrangular 736 
cut-out of a fixed area was delimited. To estimate the growth in the spot, the pixel 737 
values in this cut-out were averaged, considering the black and white scale (values from 738 
0 to 255). For each strain, the median of the 4 values was calculated according to the 739 
plate map. The z-score was calculated using median values, according to the median of a 740 
sample minus the mean of all median values, divided by the standard deviation of all 741 
median values. Strains that varied by more than 3 standard deviations (3*SD) from the 742 
mean were considered resistant.  743 
 744 
Small-scale validation assays 745 
Gene deletion of strains selected for validation were confirmed by PCR with 746 
“A_confirmation_primer” (18) and kanMX reverse 5’-CATCATTGGCAACGCTAC-3’ (for 747 
kanMX gene deletion) or natMX reverse 5’-AAGACGGTGTCGGTGGTG-3’ (for natMX gene 748 
deletion). Overnight cultures in YNB+Sc were serial diluted in a 96-well plate and 749 
stamped using a Replica plater with 48 pins (Sigma-Aldrich, Merck Group) in Petri dishes 750 
with solid media YNB+Sc containing inhibitory concentrations of xenobiotics. Cultures 751 
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were incubated for 2 days at 30°C and on subsequent days incubated at room 752 
temperature (~25°C). Plate photos were registered with ChemiDoc™ MP (Bio-Rad). 753 
Growth curves and non-linear regression of selected deletants were performed as 754 
described for IC90 determination. 755 
 756 
Data availability 757 
High-throughput sequencing data of the CGP screens have been deposited in the NCBI 758 
Short Read Archive (SRA) under BioProject PRJNA718573 (BioSamples SAMN18541664 759 
to SAMN18541685). 760 
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Figure Legends 1008 
 1009 
Figure 1. Schematic view of the experimental strategy designed to identify plasma 1010 
membrane import routes. The strategy is applied for a cytotoxic compound with an 1011 
intracellular target. For identification of a putative transporter, the deletion library of 1012 
non-essential transporters is treated with inhibitory concentrations of the compound 1013 
and resistant strains are selected. These resistant strains probably lack the transporter 1014 
responsible for the uptake of the tested compound. As exemplified, the deletion of 1015 
transporter 2 interfered in the uptake of the xenobiotic and resulted in growth of this 1016 
strain even in the presence of toxic concentrations of the tested molecule. As presented, 1017 
transporter 2 is potentially responsible for the compound’s uptake.   1018 
 1019 
Figure 2. Experimental pipeline. Using the Synthetic Genetic Array methodology, a 1020 
library of double-deletants of non-essential plasma membrane transporter encoding 1021 
genes was constructed to allow the rapid identification of kanMX deletions by barcode 1022 
sequencing. Once the sub-lethal doses of commercial xenobiotics were defined, two 1023 
approaches were employed for import-route identification. A low-throughput screening 1024 
in plate-based assay was performed for selection of strains resistant to compounds, 1025 
followed by barcode sequencing for identification of the transporter-gene deletion 1026 
responsible for the resistance phenotype. Chemical genomic profiling is a high-1027 
throughput approach employed to determine the relative abundance of transporter-1028 
gene deletion strains in the presence of a xenobiotic, and thus suggest putative 1029 
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importers and exporters. In both strategies, validation assays were conducted for 1030 
confirmation of putative transport routes.     1031 
 1032 
Figure 3. Spot test for inhibitory concentration definition. Serial dilutions (5x) of 1033 
transporter-gene double- and single-mutant pool, wild type (BY4741) and isolated 1034 
single-mutant (trx2::kanMX and cpr1::kanMX) S. cerevisiae strains spotted onto YNB+Sc 1035 
plates containing the indicated concentrations of xenobiotics. For chlorothalonil, 1036 
difenoconazole, epoxiconazole, fluconazole, ketoconazole, tebuconazole, 1,10-1037 
phenanthroline, captan, tamoxifen, and tunicamycin, it is possible to see that the 1038 
double-mutant pool library presents more resistant strains than the single-mutant pool. 1039 
For ammonium pyrrolidinedithiocarbamate, 3,4-dichloroisocoumarin, irgasan, and 1040 
mancozeb, the single-mutant library presents more resistant strains, which may be due 1041 
to the group of deletions not represented in the double gene-deletion library or because 1042 
of the cell background. 5-fluorocytosine shows a very similar pattern in the two libraries 1043 
and 8-hydroxyquinoline shows a pattern that seems to correspond to a cell background 1044 
from the double-deletion library. Other compounds did not present a selective 1045 
cytotoxicity between libraries. 1046 
 1047 
Figure 4. Selection of transporter-gene deletion strains resistant to xenobiotics. 1048 
Approximately 103 or 105 colony-forming units (CFUs) of wild type (BY4741) or 1049 
transporter-gene deletion pool were plated onto YNB + Sc agar plates with the indicated 1050 
52 
 
concentrations of xenobiotics (or solvent control – DMSO 2%) to identify putative 1051 
differences in number and size of drug-resistant colonies. Resistant transporter-gene 1052 
deletion colonies were picked for barcode identification.    1053 
 1054 
Figure 5. Relative abundance of double-mutant library strains in the presence of 1055 
cytotoxic concentrations of xenobiotics evaluated by CGP. Resistant strains (log2 fold 1056 
change > 0) indicate the potential involvement of the protein encoded by the deleted 1057 
gene in uptake of the xenobiotic (Importers). Sensitive strains (log2 fold change < 0) 1058 
indicate the potential involvement of the deleted gene’s product in efflux of the 1059 
xenobiotic (Exporters). Strains with the highest and lowest abundance were labeled for 1060 
identification.  1061 
 1062 
Figure 6. Principal components analysis of all treatments from CGP performed with our 1063 
transporter-gene double deletion library and sub lethal dose of xenobiotics. Azole 1064 
compounds group in the PCA plot, with exception of fluconazole. Agrochemical triazoles 1065 
(difenoconazole, epoxiconazole and tebuconazole) and imidazoles (clotrimazole and 1066 
ketoconazole) form two subgroups. This may indicate a similar strain composition profile 1067 
and probably an involvement of a set of transporter proteins in the carriage of these 1068 




Figure 7. Validation of double mutant resistance to 1,10-phenanthroline. The panels 1071 
present a spot-test of serial dilutions of double-deletion strains in the presence of 1,10-1072 
phenanthroline or 2% DMSO control. Combinations of mutations in genes encoding 1073 
large molecule transporters (Arn1p, Arn2p, Enb1p or Fui1p) are resistant to the drug 1074 
whereas single mutants anr1Δ, arn2Δ, enb1Δ or mutations in combination with the gene 1075 
encoding iron permease Ftr1p do not confer a growth advantage. 1076 
 1077 
Figure 8. Relationship between azole influx and efflux transporters based on CGP 1078 
results. The analysis shows a good correlation (r2 > 0.95) between proposed transport 1079 
routes for agrochemical azoles (difenoconazole, epoxiconazole and tebuconazole) 1080 
members of the 1,2,4 – triazole class and between the animal antifungals clotrimazole 1081 
and ketoconazole (r2 = 0.9728), which are members of imidazole class. A, B, C, D, E and F 1082 
presents the correlation graphs with clotrimazole, difenoconazole, epoxiconazole, 1083 
fluconazole, ketoconazole and tebuconazole, respectively, in abscissa and other 5 in 1084 
ordinate. G presents the chemical structure of the azole xenobiotics. Different colors 1085 
identify the xenobiotic represented. Strains with the highest and lowest abundance 1086 
were labeled for identification.  1087 
 1088 
Figure 9. Evaluation of resistance or sensitivity phenotypes in double-deletion strains 1089 
for putative importers and a known exporter of azoles compounds. The panels present 1090 
spot-test of serial dilutions of double-deletion strains in the presence of the 6 azoles 1091 
compounds: clotrimazole, difenoconazole, epoxiconazole, fluconazole, ketoconazole 1092 
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and tebuconazole. A. itr1Δ presented a resistance phenotype without the presence of a 1093 
second transporter deletion and in the presence of Pdr5p. pdr5Δ, as expected, 1094 
presented a sensitivity profile, confirming its importance in azole efflux. However, with 1095 
the double mutant itr1Δ pdr5Δ, a sensitive phenotype is observed, indicating a 1096 
secondary uptake route. B. and C. itr2Δ (ITR1 paralog) and nha1Δ (experimental hit for 1097 
azoles), respectively, were tested as a secondary route. Plate assays indicate that 1098 
deletion of these transporters does not confer resistance and may indicate that they are 1099 
not involved in the uptake.   1100 
  1101 
Supplemental Materials 1102 
 1103 
Table S1. Xenobiotics used in this study. Compound name, catalogue numbers and 1104 
chemical properties. 1105 
 1106 
Figure S1. Principal components analysis of all treatments from the CGP experiment, 1107 
excluding fluconazole. Exclusion of fluconazole from PCA plot revealed a different profile 1108 
for 5-fluorocytosine, the positive control of the assay. Azoles still group, with a clear 1109 
separation of the subgroups triazoles and imidazoles. 1110 
 1111 
Figure S2. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1112 
presence of inhibitory concentration of tunicamycin. Upper left panel shows a test plate 1113 
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containing tunicamycin (4 days of growth). Upper right panel shows a control plate with 1114 
DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX followed by 1115 
::kanMX) and the lower panel, the z-score for each quadruplicate. Green squares 1116 
correspond to scores 3*SD and orange squares correspond to between 2 and 3*SD. 1117 
High-density assay presents the same DMSO 2% plate as the experiment control. 1118 
 1119 
Figure S3. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1120 
presence of inhibitory concentration of tamoxifen. Upper left panel shows a test plate 1121 
containing tamoxifen (4 days of growth). Upper right panel shows a control plate with 1122 
DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX followed by 1123 
::kanMX) and the lower panel, the z-score for each quadruplicate. Green squares 1124 
correspond to scores 3*SD and orange squares correspond to between 2 and 3*SD. 1125 
High-density assay presents the same DMSO 2% plate as the experiment control. 1126 
 1127 
Figure S4. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1128 
presence of inhibitory concentration of difenoconazole. Upper left panel shows a test 1129 
plate containing difenoconazole (4 days of growth). Upper right panel shows a control 1130 
plate with DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX 1131 
followed by ::kanMX) and the lower panel, the z-score for each quadruplicate. Green 1132 
squares correspond to scores 3*SD and orange squares correspond to between 2 and 1133 




Figure S5. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1136 
presence of inhibitory concentration of epoxiconazole. Upper left panel shows a test 1137 
plate containing epoxiconazole (4 days of growth). Upper right panel shows a control 1138 
plate with DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX 1139 
followed by ::kanMX) and the lower panel, the z-score for each quadruplicate. Green 1140 
squares correspond to scores 3*SD and orange squares correspond to between 2 and 1141 
3*SD. High-density assay presents the same DMSO 2% plate as the experiment control. 1142 
 1143 
Figure S6. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1144 
presence of inhibitory concentration of tebuconazole. Upper left panel shows a test 1145 
plate containing tebuconazole (4 days of growth). Upper right panel shows a control 1146 
plate with DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX 1147 
followed by ::kanMX) and the lower panel, the z-score for each quadruplicate. Green 1148 
squares correspond to scores 3*SD and orange squares correspond to between 2 and 1149 
3*SD. High-density assay presents the same DMSO 2% plate as the experiment control.  1150 
 1151 
Figure S7. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1152 
presence of inhibitory concentration of clotrimazole. Upper left panel shows a test plate 1153 
containing clotrimazole (4 days of growth). Upper right panel shows a control plate with 1154 
DMSO 2% (4 days of growth). Middle panel presents a  plate map (::natMX followed by 1155 
::kanMX) and the lower panel, the z-score for each quadruplicate. Green squares 1156 
57 
 
correspond to scores 3*SD and orange squares correspond to between 2 and 3*SD. 1157 
High-density assay presents the same DMSO 2% plate as the experiment control.  1158 
 1159 
Figure S8. High-density assay with 308 double-deletion strains (in quadruplicate) in the 1160 
presence of inhibitory concentration of ketoconazole. Upper left panel shows a test 1161 
plate containing ketoconazole (4 days of growth). Upper right panel shows a control 1162 
plate with DMSO 2% (4 days of growth). Middle panel presents a plate map (::natMX 1163 
followed by ::kanMX) and the lower panel, the z-score for each quadruplicate. Green 1164 
squares correspond to scores 3*SD and orange squares correspond to between 2 and 1165 
3*SD. High-density assay presents the same DMSO 2% plate as the experiment control. 1166 
 1167 
Data set S1. Differential abundance of barcodes between samples treated compared to 1168 
untreated controls of 21 compounds. Each sheet corresponds to data from each 1169 
compound, specified in the sheet name. Headlines are described on the first sheet 1170 




Table 1. Transporter-gene deletion strains resistant to xenobiotics in agar plates (low-1173 
throughput) or liquid cultures (high-throughput).  1174 
Compound 
Low-Throughput Assay High-Throughput Assay 
[µM] Hits [µM] Hits* (log2 fold change) 
5-Fluorocytosine 8 7x fcy2Δ, ftr1Δ, tat2Δ 20 
fui1Δ (2.22), tat1Δ (1.23), adp1Δ (1.27), 
bap3Δ (0.93), fcy2Δ (8.44), azr1Δ (1.06), 
gal2Δ (0.59), atr2Δ (0.96), nrt1Δ (1.24), 
pdr12Δ (1.84), ssu1Δ (2.68), aqy1Δ (1.14) 
Clotrimazole 10 
fui1Δ, mal31Δ, tpo2Δ, cch1Δ, 
mal11Δ, arn2Δ, 2x hxt1Δ, 
opt1Δ, 4x nha1Δ, mep2Δ, lyp1Δ, 
alp1Δ, thi72Δ, pma2Δ 
2 nha1Δ (0.72) 
Ketoconazole 25 
gnp1Δ, mep1Δ, tok1Δ, jen1Δ, 
14x nha1Δ 




dtr1Δ, snq2Δ, itr1Δ, gnp1Δ, 
tna1Δ, arn1Δ, arn2Δ, gap1Δ, 6x 
nha1Δ, mmt1Δ 
0.16 
adp1Δ (0.70), itr1Δ (0.90), ftr1Δ (1.08), 
tna1Δ (0.63), yor1Δ (0.81), tpo5Δ (1.35), 
tpo1Δ (0.91), nha1Δ (2.51), smf1Δ (0.93), 
tpo4Δ (0.73) 
Epoxiconazole Pestanal ® 0.8 
pho89Δ, 2x hxt3Δ, ato3Δ, 2x 
itr1Δ, 2x cch1Δ, dur3Δ, hxt5Δ, 
nft1Δ, ybt1Δ, mmt1Δ, mch5Δ, 
pma2Δ, aqy1Δ 
0.032 
adp1Δ (0.75), snq2Δ (1.12), itr1Δ (1.52), 
ftr1Δ (1.94), tna1Δ (0.67), yor1Δ (0.97), 
gef1Δ (0.69), tpo5Δ (1.96), tpo1Δ (1.11), 
ybt1Δ (0.61), nha1Δ (3.93), smf1Δ (1.51), 
tpo4Δ (0.76), dip5Δ (0.67), ctr1Δ (0.76) 
Tebuconazole Pestanal ® 20 
bap3Δ, 2x itr1Δ, agp3Δ, hnm1Δ, 
2x mep1Δ, hxt8Δ, nft1Δ, prm6Δ, 
atr1Δ, fet4Δ, tpo4Δ, mch5Δ, 
pma2Δ, aqy1Δ 
0.32 
adp1Δ (0.69), itr1Δ (1.04), ftr1Δ (0.94), 
tna1Δ (0.82), yor1Δ (0.81), tpo5Δ (1.19), 
tpo1Δ (0.73), nha1Δ (2.67), smf1Δ (0.84), 
tpo4Δ (0.53), ctr1Δ (0.65) 
Fluconazole 100 
3x qdr3Δ, tat1Δ, agp1Δ, ady2Δ, 
adp1Δ, yor1Δ, arn1Δ, hxt4Δ, 
gex2Δ, bor1Δ, hol1Δ, enb1Δ, 
nrt1Δ, ssu1Δ, aqy1Δ 
75 
seo1Δ (1.60), flr1Δ (1.83), qdr3Δ (2.72), 
bap2Δ (2.57), tat1Δ (2.66), pca1Δ (1.76), 
pho89Δ (1.50), mal31Δ (2.57), ady2Δ 
(1.73), adp1Δ (2.48), git1Δ (1.66), sit1Δ 
(1.62), yor1Δ (2.54), arn1Δ (1.98), hxt4Δ 
(2.79), hxt1Δ (2.68), hxt5Δ (2.39), qdr2Δ 
(5.96), bor1Δ (1.17), hol1Δ (5.57), mch5Δ 
(1.54) 
1,10-Phenanthroline 35 
2x fui1Δ, adp1Δ, itr1Δ, fcy2Δ, 
tpo2Δ, arn1Δ, arn2Δ, tok1Δ, 
mid1Δ, enb1Δ, pdr5Δ 
10 No hits 
3,4-Dichloroisocoumarin 16 
itr1Δ, YFL040WΔ, hxt1Δ, kch1Δ, 
mmp1Δ, prm6Δ, lyp1Δ, 2x 
10 No hits 
59 
 




pca1Δ, 2x fen2Δ, sit1Δ, ftr1Δ, 
mep1Δ, 2x arn2Δ, qdr1Δ, 2x 
dal5Δ, hol1Δ, aus1Δ 
50 ctr1Δ (1.35) 
Ammonium 
pyrrolidinedithiocarbamate 
4 dtr1Δ, zrt1Δ, pdr11Δ, itr2Δ N.P. 
Artesunate 400 
2x flr1Δ, 2x can1Δ, YFL040WΔ, 
alr2Δ, agp3Δ, arn1Δ, hxt4Δ, 
tpo1Δ, ybt1Δ, atr2Δ, bor1Δ 
200 
tna1Δ (0.79), tpo1Δ (0.72), nha1Δ (0.91), 
hxt17Δ (0.72) 
Cantharidin 60 
2x pca1Δ, fen2Δ, zrt1Δ, yor1Δ, 
dur3Δ, 2x hxt1Δ, pdr11Δ, qdr1Δ, 
trk1Δ, hxt14Δ, itr2Δ, tpo4Δ  
N.P. 
Captan Pestanal ® 5 
dtr1Δ, bap3Δ, fcy2Δ, kch1Δ, 
jen1Δ, prm6Δ, mid1Δ, tpo4Δ, 
mch5Δ, put4Δ, sam3Δ, sge1Δ 




agp1Δ, ady2Δ, adp1Δ, ato3Δ, 
tna1Δ, yor1Δ, pdr11Δ, kch1Δ, 
nft1Δ, ybt1Δ, nha1Δ, atr1Δ, 
hxt14Δ, pdr5Δ 
200 
fur4Δ (0.77), tat1Δ (1.77), cin10Δ (0.99), 
hnm1Δ (0.55), tna1Δ (2.01), nft1Δ (0.77), 
nha1Δ (2.04), aqr1Δ (0.53), tat2Δ (1.08), 
pdr5Δ (1.29), ctr1Δ (0.99) 
Chlorothalonil Pestanal ® 0.1, 1 
fur4Δ, hxt3Δ, ato3Δ, gnp1Δ, 4x 
zrt1Δ, nft1Δ, sul2Δ, atr1Δ, 
bor1Δ, bio5Δ, pdr5Δ, mch5Δ, 
dip5Δ 
0.8 atr1Δ (0.77) 
Dazomet Pestanal ® 15, 20 
3x YDL199CΔ, gex2Δ, mep2Δ, 
smf1Δ, ssu1Δ, tpo3Δ 
N.P. 
Iprobenfos Pestanal ® 200 
flr1Δ, qdr3Δ, git1Δ, hxt10Δ, 
mal11Δ, sul2Δ, hxt2Δ, aus1Δ, 
thi72Δ, tpo4Δ, put4Δ, ssu1Δ, 
aqy1Δ 
200 No hits 
Irgasan 40, 50 
pca1Δ, stl1Δ, alr2Δ, trk1Δ, 
aqr1Δ, 2x mep2Δ, lyp1Δ, 2x 
mid1Δ, ato2Δ, 2x aus1Δ, sam3Δ 
15 fen2Δ (1.94), arn1Δ (0.52), arn2Δ (0.69) 
Mancozeb Pestanal ® 
10, 
20, 30 
sul1Δ, stl1Δ, zrt1Δ, opt1Δ, 
nha1Δ, atr1Δ 
N.P. 
N-Phenylanthranilic Acid - no resistant selected 100 
snq2Δ (0.68), tna1Δ (0.87), mid1Δ (0.76), 
pdr5Δ (1.01) 
Tamoxifen 365 
YDL199CΔ, opt1Δ, kch1Δ, dal5Δ, 
7x tpo5Δ, 3x nha1Δ, atr1Δ, 
mep2Δ, itr2Δ, mch5Δ 
40 adp1Δ (0.50), tna1Δ (1.18) 
Tunicamycin 4 
fui1Δ, flr1Δ, 11x fur4Δ, qdr3Δ, 
mal31Δ, zrt1Δ, nft1Δ, tpo4Δ, 
aqy1Δ 
1 No hits 
60 
 
* log2 fold change≥0.5; p-value adjusted for multiple tests (padj) ≤ 0.1; p-value ≤ 0.001. 1175 
N.P. indicate assays not performed. Bold deletant names correspond to those that are 1176 
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